Home > Quotes > SNGX

Soligenix, Inc. Stock Quote & Summary Data

SNGX 
$1.5
*  
0.02
  negative  
1.32%
Get SNGX Alerts
*Delayed - data as of Jun. 19, 2013 


Community Rating:
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 | Sponsored

1 Year Target: 5
Today's High/Low:  / 
Share Volume:
50 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today’s trading to the average daily volume. N/A
Previous Close: $ 1.52
52 Week High /Low: $ 2.13 / $ 0.23
P/E Ratio: NE
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year. NE
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ -0.34
Annualized dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield 0 %
Beta 0

 Intraday Chart

5d | 1m | 6m | 12m | More Charting




News Headlines for SNGX

FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
6/3/2013 7:30:00 AM - PR Newswire
FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
6/3/2013 7:30:00 AM - PR Newswire
Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn's Disease
5/15/2013 7:00:00 AM - PR Newswire
Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn's Disease
5/15/2013 7:00:00 AM - PR Newswire
Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments
5/3/2013 7:00:00 AM - PR Newswire
 

Consensus Recommendation